1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with lrrk2-in1 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Froehlich, T; Gillardon, F; Gloeckner, CJ; Hengerer, B; Kremmer, E; Ueffing, M | 1 |
1 other study(ies) available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and lrrk2-in1
Article | Year |
---|---|
ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2?
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adenosine Triphosphate; Amino Acid Sequence; Amino Acid Substitution; Animals; Antibodies, Monoclonal; Antigen-Antibody Reactions; Benzodiazepinones; Binding, Competitive; Enzyme Activation; Epitopes; HEK293 Cells; Humans; Immunoprecipitation; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Parkinson Disease; Phosphorylation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Pyrimidines; Recombinant Proteins; Swiss 3T3 Cells | 2013 |